Microbix Biosystems, Inc.  

(Public, TSE:MBX)   Watch this stock  
Find more results for MBX
0.000 (0.00%)
Dec 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.66 - 0.67
52 week 0.15 - 0.90
Open 0.67
Vol / Avg. 9,249.00/116,183.00
Mkt cap 51.34M
P/E 38.51
Div/yield     -
EPS 0.02
Shares 77.79M
Beta -1.00
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 10.32% 0.02%
Operating margin 14.44% 2.22%
EBITD margin - 14.90%
Return on average assets 5.45% 0.01%
Return on average equity 11.33% 0.03%
Employees 20 -
CDP Score - -


265 Watline Ave
+1-905-3618910 (Phone)
+1-905-3618911 (Fax)

Website links


Microbix Biosystems Inc. develops biological products and technologies. The Company has a Virology Products business, including the manufacturing and sale of cell culture-based biological products and the licensing of technologies. The Company has also developed VIRUSMAX (a virus yield enhancement technology), and Kinlytic (a thrombolytic drug), and is developing LumiSort a semen sexing technology. LumiSort is next generation instrument based (cytometric) technology that will improve the yield and quality of sexed semen while increasing the speed of sex-sorting by an order of magnitude over methods used in the livestock industry. Urokinase is a natural human protein that stimulates the human body�s blood clot-dissolving processes. VIRUSMAX technology is a process for recovery of more viruses from influenza virus-infected chick embryos (eggs) to enhance influenza vaccine production.

Officers and directors

William J. Gastle Executive Chairman of the Board
Vaughn C. Embro-Pantalony President, Chief Executive Officer, Director
James A. Long Chief Financial Officer
Mark A. Cochran Director
Peter M. Blecher Independent Director
Cameron L. Groome Independent Director
Martin A. Marino Independent Director
Andrew C. Pollock Independent Director